pioglitazone has been researched along with Anterior Choroidal Artery Infarction in 10 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Present study was carried out to investigate the possible neuroprotective effect of pioglitazone, an antidiabetic agent, peroxisome proliferator-activated receptor gamma (PPARgamma) agonist on acute phase changes in mice model of cerebral ischemia induced by Bilateral Common Carotid artery Occlusion (BCCAO)." | 7.76 | Neuroprotective effect of pioglitazone on acute phase changes induced by partial global cerebral ischemia in mice. ( Aggarwal, R; Chakrabarti, A; Medhi, B, 2010) |
| "The role of the phosphorylated signal transducer and activator of transcription-3 (p-STAT3) after cerebral ischemia by the peroxisome proliferator-activated receptor γ (PPARγ) agonist pioglitazone (PGZ) remains controversial." | 3.78 | Activation of signal transducer and activator of transcription-3 by a peroxisome proliferator-activated receptor gamma agonist contributes to neuroprotection in the peri-infarct region after ischemia in oophorectomized rats. ( Kageji, T; Kinouchi, T; Kitazato, KT; Matsushita, N; Nagahiro, S; Satomi, J; Shimada, K; Sumiyoshi, M; Tada, Y; Yagi, K, 2012) |
| "Present study was carried out to investigate the possible neuroprotective effect of pioglitazone, an antidiabetic agent, peroxisome proliferator-activated receptor gamma (PPARgamma) agonist on acute phase changes in mice model of cerebral ischemia induced by Bilateral Common Carotid artery Occlusion (BCCAO)." | 3.76 | Neuroprotective effect of pioglitazone on acute phase changes induced by partial global cerebral ischemia in mice. ( Aggarwal, R; Chakrabarti, A; Medhi, B, 2010) |
| "Pre-treatment with fenofibrate and pioglitazone in addition to their combination improved neurobehavioral dysfunction, reduced cerebral infarct volume, attenuated inflammatory and apoptotic markers and ameliorated histopathological changes in I/R injured rats." | 1.56 | The impact of single and combined PPAR-α and PPAR-γ activation on the neurological outcomes following cerebral ischemia reperfusion. ( Abdelrehim, AB; Ahmed, AF; Heeba, GH; Shehata, AHF, 2020) |
| "Pioglitazone or vehicle was infused intracerebroventricularly over a 5-day period before, during and 24 or 48 h after middle cerebral artery occlusion." | 1.36 | Peroxisome-proliferator-activated receptors gamma and peroxisome-proliferator-activated receptors beta/delta and the regulation of interleukin 1 receptor antagonist expression by pioglitazone in ischaemic brain. ( Culman, J; Glatz, T; Gohlke, P; Herdegen, T; Nguyen-Ngoc, M; Stöck, I; Zhao, Y, 2010) |
| "Pioglitazone treatment reduced the infarct size and improved neurological functions." | 1.35 | Peroxisome proliferator-activated receptorsgamma (PPARgamma) differently modulate the interleukin-6 expression in the peri-infarct cortical tissue in the acute and delayed phases of cerebral ischaemia. ( Culman, J; Gohlke, P; Herdegen, T; Patzer, A; Stöck, I; Zhao, Y, 2008) |
| "Rosiglitazone treatment curtailed the post-ischemic expression of the pro-inflammatory genes interleukin-1beta, interleukin-6, macrophage inflammatory protein-1alpha, monocyte chemoattractant protein-1, cyclooxygenase-2, inducible nitric oxide synthase, early growth response-1, CCAAT/enhancer binding protein-beta and nuclear factor-kappa B, and increased the expression of the anti-oxidant enzymes catalase and copper/zinc-superoxide dismutase." | 1.34 | Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents. ( Bowen, KK; Feinstein, DL; Kapadia, R; Liang, J; Satriotomo, I; Tureyen, K; Vemuganti, R, 2007) |
| "Pioglitazone or vehicle were i." | 1.33 | The intracerebral application of the PPARgamma-ligand pioglitazone confers neuroprotection against focal ischaemia in the rat brain. ( Culman, J; Gohlke, P; Herdegen, T; Patzer, A; Zhao, Y, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (50.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shehata, AHF | 1 |
| Ahmed, AF | 1 |
| Abdelrehim, AB | 1 |
| Heeba, GH | 1 |
| Patzer, A | 2 |
| Zhao, Y | 3 |
| Stöck, I | 2 |
| Gohlke, P | 3 |
| Herdegen, T | 3 |
| Culman, J | 3 |
| Lee, SR | 1 |
| Kim, HY | 1 |
| Hong, JS | 1 |
| Baek, WK | 1 |
| Park, JW | 1 |
| Glatz, T | 1 |
| Nguyen-Ngoc, M | 1 |
| Medhi, B | 1 |
| Aggarwal, R | 1 |
| Chakrabarti, A | 1 |
| Blankenship, D | 1 |
| Niemi, J | 1 |
| Hilow, E | 1 |
| Karl, M | 1 |
| Sundararajan, S | 1 |
| Kinouchi, T | 1 |
| Kitazato, KT | 1 |
| Shimada, K | 1 |
| Yagi, K | 1 |
| Tada, Y | 1 |
| Matsushita, N | 1 |
| Sumiyoshi, M | 1 |
| Satomi, J | 1 |
| Kageji, T | 1 |
| Nagahiro, S | 1 |
| Tureyen, K | 1 |
| Kapadia, R | 1 |
| Bowen, KK | 1 |
| Satriotomo, I | 1 |
| Liang, J | 1 |
| Feinstein, DL | 1 |
| Vemuganti, R | 1 |
10 other studies available for pioglitazone and Anterior Choroidal Artery Infarction
| Article | Year |
|---|---|
The impact of single and combined PPAR-α and PPAR-γ activation on the neurological outcomes following cerebral ischemia reperfusion.
Topics: Animals; Apoptosis; Brain; Brain Ischemia; Cerebral Infarction; Disease Models, Animal; Drug Therapy | 2020 |
Peroxisome proliferator-activated receptorsgamma (PPARgamma) differently modulate the interleukin-6 expression in the peri-infarct cortical tissue in the acute and delayed phases of cerebral ischaemia.
Topics: Animals; Anti-Inflammatory Agents; Brain Ischemia; Cerebral Infarction; Disease Models, Animal; Ence | 2008 |
PPARgamma agonist pioglitazone reduces matrix metalloproteinase-9 activity and neuronal damage after focal cerebral ischemia.
Topics: Animals; Brain Ischemia; Cerebral Infarction; Cytoprotection; Male; Matrix Metalloproteinase Inhibit | 2009 |
Peroxisome-proliferator-activated receptors gamma and peroxisome-proliferator-activated receptors beta/delta and the regulation of interleukin 1 receptor antagonist expression by pioglitazone in ischaemic brain.
Topics: Animals; Brain; Brain Ischemia; Cerebral Infarction; Infarction, Middle Cerebral Artery; Interleukin | 2010 |
Neuroprotective effect of pioglitazone on acute phase changes induced by partial global cerebral ischemia in mice.
Topics: Acute-Phase Reaction; Animals; Antioxidants; Brain Edema; Brain Ischemia; Carotid Artery, Common; Ce | 2010 |
Oral pioglitazone reduces infarction volume and improves neurologic function following MCAO in rats.
Topics: Administration, Oral; Animals; Brain Ischemia; Cerebral Infarction; Disease Models, Animal; Hypoglyc | 2011 |
Activation of signal transducer and activator of transcription-3 by a peroxisome proliferator-activated receptor gamma agonist contributes to neuroprotection in the peri-infarct region after ischemia in oophorectomized rats.
Topics: Animals; Apoptosis; Basal Ganglia; Brain; Brain Ischemia; Caspase 3; Cell Nucleus; Cerebral Infarcti | 2012 |
The intracerebral application of the PPARgamma-ligand pioglitazone confers neuroprotection against focal ischaemia in the rat brain.
Topics: Animals; Brain; Brain Edema; Brain Ischemia; Cerebral Infarction; Disease Models, Animal; Encephalit | 2005 |
[New subgroup analysis of the PROactive Study. Risk for recurrent stroke cut in half].
Topics: Cerebral Infarction; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Hum | 2006 |
Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents.
Topics: Anilides; Animals; Cerebral Infarction; Chemotaxis, Leukocyte; Cytokines; Diabetes Mellitus, Type 2; | 2007 |